Article metrics

Download PDFPDF
559 Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)

 

Online download statistics by month:

Online download statistics by month: March 2024 to June 2024

AbstractFullPdf
Mar 202414001
Apr 20246403
May 20245500
Jun 20241400
Total27304